C.£1.5 million Contract Extension
IXICO plc has announced a contract extension worth approximately £1.5 million in additional revenues over the next three years with a leading international pharmaceutical company, related to a Phase 2 clinical trial for Huntington's Disease. This extension highlights the continued progress of the trial and the value of IXICO's AI-driven platform and neuroscience imaging expertise in drug development.
Select text to share a quote on X · sign in to keep highlights & notes in your IXI notes
The following amendment has been made to the "c.£1.5 million Contract Extension" announcement released at 07:00 on 12 February 2026:
The reference in the quote to "Thanks to this contract extension IXICO has secured over £2.7m in new revenues with 2 existing clients in the last 2 months" has been removed.
IXICO plc
("IXICO", the "Company" or the "Group")
c.£1.5 million contract extension on global Phase 2 clinical trial
12 February 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced the extension of an existing contract with one of the world's leading international pharmaceutical companies following the continued progress of a Phase 2 clinical trial in Huntington's Disease.
The contract extension is worth an additional c.£1.5 million in revenues to IXICO over the next three years.
Bram Goorden, CEO of IXICO, commented: "This contract extension is an example of how IXICO's compelling IXI™ technology platform and neurological disease expertise consistently deliver gold standard outcomes for biopharma customers as they advance drug development in such a devastating neurological disease."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.